2019 American Transplant Congress

June 1-5, 2019 in Boston, MA

View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Long-Term Outcomes of Early Conversion to Sirolimus-Based Immunosuppression in Children with Living Donor Kidney Transplants

B. Stotter¹, S. Lui¹, E. Weller², L. Ganapathi¹, M. Ferguson¹, A. Traum¹, M. Somers¹, N. Rodig¹
Long-Term Outcomes of Eculizumab-Treated Positive Crossmatch Recipients: Allograft Survival, Histologic Findings, and Natural History of the Donor-Specific Antibodies

C. Schinstock, A. Bentall, S. Byron, L. Cornell, M. Everly, M. Gandhi, M. Stegall
Long-Term Outcomes of Elderly Living Donors: A Nationwide Population-Based Study

H. Yoon¹, Y. Kim², S. Shin¹, J. Ahn³, C. Yang¹, B. Chung¹
Long-Term Outcomes of Older Kidney-Transplant Recipients: A Single-Center Experience

S. Sultan, M. Aull, M. Lubetzky, A. Watkins, S. Kapur
Long-Term Survival after Kidney-Pancreas Transplantation: Lessons from World Largest Series of Long-Term Survivors

S. Parajuli, F. Aziz, N. Garg, B. Muth, A. Djamali, R. Redfield, D. Kaufman, J. Odorico, D. Mandelbrot, H. Sollinger
Long-Term Survival Analysis of Kidney Transplant Recipients Receiving Mizoribine as a Maintenance Immunosuppressant

J. Kim¹, D. Lee¹, J. Oh¹, J. Lee¹, H. Kim¹, Y. Son²
Longer-Term Outcomes for Hepatitis C Virus Negative Recipients of Kidneys from Hepatitis C Virus Nucleic Acid Test Positive Donors: The THINKER Trial

P. Reese¹, P. Abt¹, E. Blumberg¹, R. Bloom¹, D. Sawinski¹, P. Porrett¹, A. Woodards¹, K. Reddy¹, V. van Deerlin¹, R. Hasz², M. Levine¹, R. McLean¹, A. Sicilia¹, D. Goldberg¹
Loss of FXR Exacerbates Liver Damage by Activating NLRP3 Inflammasome Induced Pyroptosis in Liver Ischemia Reperfusion Injury

Z. Zhu, Y. Zhang, Y. Tang, S. Huang, Q. Zhao, W. Ju, Z. Guo, X. He
Low Dose Anti-Thymocyte Globulin is Enough to Prevent Acute Cellular Rejection in Kidney Transplant

P. W. Baron¹, J. Weissman², F. Fazeli³, C. Zuppan⁴, R. Villicana³, P. Wai¹, L. Beeson⁵, M. De Vera¹
Low Dose Thymoglobulin Has No Disadvantages to Standard Higher Dose: A Report of the Midwest Pediatric Nephrology Consortium

I. Ashoor¹, R. Beyl², C. Gupta³, A. Jain⁴, S. Kiessling⁵, H. Patel⁶, J. Sherbotie⁷, D. J. Weaver Jr⁸, R. Zahr⁹, V. Dharnidharka¹⁰

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z